AU2008290531A1 - Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis - Google Patents

Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis Download PDF

Info

Publication number
AU2008290531A1
AU2008290531A1 AU2008290531A AU2008290531A AU2008290531A1 AU 2008290531 A1 AU2008290531 A1 AU 2008290531A1 AU 2008290531 A AU2008290531 A AU 2008290531A AU 2008290531 A AU2008290531 A AU 2008290531A AU 2008290531 A1 AU2008290531 A1 AU 2008290531A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
alkoxy
compound according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008290531A
Other languages
English (en)
Inventor
Michael Daniel Goldsmith
Clifford John Harris
Angus Macleod
Dale Robert Mitchell
Nicholas John Palmer
Christophe Claude Parsy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofocus DPI Ltd
Original Assignee
Biofocus DPI Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus DPI Ltd filed Critical Biofocus DPI Ltd
Publication of AU2008290531A1 publication Critical patent/AU2008290531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008290531A 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis Abandoned AU2008290531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0716292.8A GB0716292D0 (en) 2007-08-21 2007-08-21 Imidazopyrazine compounds
GB0716292.8 2007-08-21
PCT/EP2008/060896 WO2009024585A2 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Publications (1)

Publication Number Publication Date
AU2008290531A1 true AU2008290531A1 (en) 2009-02-26

Family

ID=38566736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008290531A Abandoned AU2008290531A1 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Country Status (20)

Country Link
US (1) US8362018B2 (enExample)
EP (2) EP2567960A3 (enExample)
JP (1) JP2010536825A (enExample)
KR (1) KR20100081294A (enExample)
CN (1) CN101835780B (enExample)
AU (1) AU2008290531A1 (enExample)
BR (1) BRPI0815717A2 (enExample)
CA (1) CA2707521A1 (enExample)
CY (1) CY1113872T1 (enExample)
DK (1) DK2193131T3 (enExample)
ES (1) ES2404415T3 (enExample)
GB (1) GB0716292D0 (enExample)
HR (1) HRP20130202T1 (enExample)
MX (1) MX2010001733A (enExample)
NZ (1) NZ584108A (enExample)
PL (1) PL2193131T3 (enExample)
PT (1) PT2193131E (enExample)
SI (1) SI2193131T1 (enExample)
WO (1) WO2009024585A2 (enExample)
ZA (1) ZA201002009B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
PL2491028T3 (pl) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
WO2011071730A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
ES2551407T3 (es) * 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
WO2011151259A1 (en) 2010-06-01 2011-12-08 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines
CA2821819A1 (en) 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651944B1 (en) * 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103429591A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) * 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
WO2016206999A1 (en) * 2015-06-24 2016-12-29 Apodemus Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
HK1250945A1 (zh) * 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
IL276013B2 (en) 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
JP7309725B2 (ja) 2018-08-21 2023-07-18 杏林製薬株式会社 ２環性ヘテロ芳香環誘導体
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN109369545B (zh) * 2018-12-14 2020-04-10 东营曜康医药科技有限公司 2-甲基-5-甲酸吡嗪的合成工艺
CN116574099A (zh) 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
JP7824232B2 (ja) * 2020-06-01 2026-03-04 エフ． ホフマン－ラ ロシュ アーゲー 新規イミダゾピラジン誘導体
EP4161930A1 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Novel imidazo-pyrazine derivatives
CN113929633A (zh) * 2021-10-27 2022-01-14 山东大学 一种法匹拉韦的合成方法及其应用
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN115489188B (zh) * 2022-10-09 2023-08-29 安徽国风新材料股份有限公司 一种家居保护用聚酯薄膜及其制备方法
EP4623911A1 (en) 2024-03-25 2025-10-01 ETH Zurich Pi4kb inhibitors for the treatment of fatty liver disease
EP4623912A1 (en) 2024-03-25 2025-10-01 ETH Zurich A method for defattening a steatotic liver ex vivo

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
WO2001089364A2 (en) 2000-05-23 2001-11-29 Washington University Hcv variants
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
AU2002225895A1 (en) 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
DE60128835T2 (de) 2000-12-22 2008-03-20 Boehringer Ingelheim (Canada) Ltd., Laval Selbstreplizierendes rna-molekül aus hepatitis-c-virus
EP2050822B1 (en) 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
EP1363702A4 (en) 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
DE60317353T2 (de) * 2002-09-23 2008-08-28 Schering Corp. Imidazopyrazine als cdk-inhibitoren
AU2007200401A1 (en) * 2002-09-23 2007-02-22 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7807455B2 (en) 2003-02-13 2010-10-05 Merck Sharp & Dohme Corp. Method to confer cell culture replication activity to different Hepatitis C virus isolates
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
CA2628455A1 (en) 2005-11-10 2007-05-24 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
US20100144743A1 (en) 2006-09-05 2010-06-10 Board Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
EP2079746A2 (en) 2006-11-08 2009-07-22 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
US8243049B2 (en) 2006-12-20 2012-08-14 3M Innovative Properties Company Untethered stylus employing low current power converter
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Also Published As

Publication number Publication date
BRPI0815717A2 (pt) 2015-02-10
DK2193131T3 (da) 2013-04-22
ES2404415T3 (es) 2013-05-27
CY1113872T1 (el) 2016-07-27
KR20100081294A (ko) 2010-07-14
EP2193131B1 (en) 2013-01-30
HK1143810A1 (en) 2011-01-14
SI2193131T1 (sl) 2013-06-28
CA2707521A1 (en) 2009-02-26
EP2567960A3 (en) 2013-06-05
PL2193131T3 (pl) 2013-07-31
CN101835780A (zh) 2010-09-15
NZ584108A (en) 2012-06-29
MX2010001733A (es) 2010-07-06
WO2009024585A3 (en) 2009-08-06
WO2009024585A2 (en) 2009-02-26
US8362018B2 (en) 2013-01-29
EP2567960A2 (en) 2013-03-13
JP2010536825A (ja) 2010-12-02
CN101835780B (zh) 2013-09-18
ZA201002009B (en) 2010-12-29
EP2193131A2 (en) 2010-06-09
PT2193131E (pt) 2013-04-04
GB0716292D0 (en) 2007-09-26
US20110166147A1 (en) 2011-07-07
HRP20130202T1 (hr) 2013-04-30

Similar Documents

Publication Publication Date Title
EP2193131B1 (en) Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis
AU2020202600B2 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TWI399380B (zh) 抗病毒化合物
JP2017008058A (ja) ５，５−縮合アリーレン又はヘテロアリーレンｃ型肝炎ウイルス阻害剤
KR20150040266A (ko) 플라비바이러스과 바이러스의 마크로시클릭 저해인자
AU2009335904A1 (en) HCV NS3 protease inhibitors
KR20110005888A (ko) 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체
KR20100118991A (ko) 매크로시클릭 세린 프로테아제 억제제
AU2016366546A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
TW201036612A (en) Antiviral compounds
CN104936962B (zh) 治疗活性的噁唑啉衍生物
AU2022253683A1 (en) Deuterated dhodh inhibitors
WO2012109398A1 (en) Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2014005129A1 (en) Cyanoguanidines and their use as antiviral agents
JP2011529085A (ja) 抗ウイルス化合物
EP2953461B1 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
Bjornson et al. Inhibitors of Hepatitis C virus
HK1143810B (en) Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
EP2585448A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
US20130203706A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application